Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murine CD19 CAR-T for R/R B-ALL and B-NHL
NCT04532281Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of murine CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Nov 2020; status: recruiting.
02
Drugs
murine CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04532281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532281.